JP2020063263A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020063263A5 JP2020063263A5 JP2019217044A JP2019217044A JP2020063263A5 JP 2020063263 A5 JP2020063263 A5 JP 2020063263A5 JP 2019217044 A JP2019217044 A JP 2019217044A JP 2019217044 A JP2019217044 A JP 2019217044A JP 2020063263 A5 JP2020063263 A5 JP 2020063263A5
- Authority
- JP
- Japan
- Prior art keywords
- hematopoietic stem
- cells
- pge
- activity
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 8
- 150000003180 prostaglandins Chemical class 0.000 claims 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 3
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 238000002659 cell therapy Methods 0.000 claims 2
- 210000004700 fetal blood Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023001015A JP2023052244A (ja) | 2008-11-06 | 2023-01-06 | 造血幹細胞の生着手順を強化するための材料および方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11201808P | 2008-11-06 | 2008-11-06 | |
| US61/112,018 | 2008-11-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017195168A Division JP2018048156A (ja) | 2008-11-06 | 2017-10-05 | 造血幹細胞の生着手順を強化するための材料および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023001015A Division JP2023052244A (ja) | 2008-11-06 | 2023-01-06 | 造血幹細胞の生着手順を強化するための材料および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020063263A JP2020063263A (ja) | 2020-04-23 |
| JP2020063263A5 true JP2020063263A5 (https=) | 2020-09-03 |
Family
ID=42153284
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534934A Expired - Fee Related JP5846915B2 (ja) | 2008-11-06 | 2009-11-06 | 造血幹細胞の生着手順を強化するための材料および方法 |
| JP2015134076A Expired - Fee Related JP6632822B2 (ja) | 2008-11-06 | 2015-07-03 | 造血幹細胞の生着手順を強化するための材料および方法 |
| JP2017195168A Withdrawn JP2018048156A (ja) | 2008-11-06 | 2017-10-05 | 造血幹細胞の生着手順を強化するための材料および方法 |
| JP2019217044A Withdrawn JP2020063263A (ja) | 2008-11-06 | 2019-11-29 | 造血幹細胞の生着手順を強化するための材料および方法 |
| JP2023001015A Pending JP2023052244A (ja) | 2008-11-06 | 2023-01-06 | 造血幹細胞の生着手順を強化するための材料および方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534934A Expired - Fee Related JP5846915B2 (ja) | 2008-11-06 | 2009-11-06 | 造血幹細胞の生着手順を強化するための材料および方法 |
| JP2015134076A Expired - Fee Related JP6632822B2 (ja) | 2008-11-06 | 2015-07-03 | 造血幹細胞の生着手順を強化するための材料および方法 |
| JP2017195168A Withdrawn JP2018048156A (ja) | 2008-11-06 | 2017-10-05 | 造血幹細胞の生着手順を強化するための材料および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023001015A Pending JP2023052244A (ja) | 2008-11-06 | 2023-01-06 | 造血幹細胞の生着手順を強化するための材料および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US9107909B2 (https=) |
| EP (3) | EP2362733B1 (https=) |
| JP (5) | JP5846915B2 (https=) |
| CN (4) | CN108379292A (https=) |
| AU (4) | AU2009313290B2 (https=) |
| CA (3) | CA3203374A1 (https=) |
| ES (1) | ES2845641T3 (https=) |
| PT (1) | PT3031907T (https=) |
| WO (1) | WO2010054271A1 (https=) |
| ZA (1) | ZA201804932B (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296832A (en) | 2005-10-18 | 2022-11-01 | Nat Jewish Health | Process of preparing red blood cells using conditionally immortalized long-term hematopoietic stem cells and erythropoietin |
| SG10201803982TA (en) | 2008-05-16 | 2018-07-30 | Taiga Biotechnologies Inc | Antibodies and processes for preparing the same |
| DK3339321T3 (da) | 2008-08-28 | 2021-06-21 | Taiga Biotechnologies Inc | Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc |
| CN108379292A (zh) | 2008-11-06 | 2018-08-10 | 印第安纳大学研究与技术公司 | 增强造血干细胞植入过程的材料和方法 |
| US10813917B2 (en) | 2009-12-11 | 2020-10-27 | Medregen, Llc | Treatment methods utilizing stem cell mobilizers and immunosuppressive agents |
| ES2654994T3 (es) * | 2010-08-12 | 2018-02-15 | Fate Therapeutics, Inc. | Terapia mejorada con células madre y precursoras hematopoyéticas |
| US10213464B2 (en) * | 2011-01-13 | 2019-02-26 | Scipharm Sarl | Method for enhancing engraftment of haematopoetic stem cells |
| ES2769270T3 (es) * | 2011-09-30 | 2020-06-25 | Bluebird Bio Inc | Compuestos para transducción viral mejorada |
| EP2785350B1 (en) | 2011-12-02 | 2018-05-02 | Fate Therapeutics, Inc. | Improved methods of treating ischemia |
| JP6220791B2 (ja) | 2011-12-02 | 2017-10-25 | フェイト セラピューティクス，インコーポレイテッド | 増強された幹細胞組成物 |
| US9233127B2 (en) | 2012-02-29 | 2016-01-12 | University Of Virginia Patent Foundation | Compositions and methods for CXCR4 signaling and umbilical cord blood stem cell engraftment |
| WO2014015318A1 (en) * | 2012-07-19 | 2014-01-23 | Bluebird Bio, Inc. | Soluble compounds for improved gene therapy methods |
| US9789135B2 (en) * | 2012-07-20 | 2017-10-17 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| US20150216903A1 (en) * | 2012-08-10 | 2015-08-06 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| KR102503695B1 (ko) | 2013-02-28 | 2023-02-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 줄기세포를 동원하기 위한 방법 및 조성물 |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| WO2014150602A1 (en) | 2013-03-15 | 2014-09-25 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| US9943545B2 (en) * | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| CN105658217B (zh) | 2013-04-29 | 2021-03-19 | 约翰霍普金斯大学 | 经由自体干细胞动员的创伤愈合 |
| KR101489861B1 (ko) * | 2013-05-07 | 2015-02-05 | 경북대학교 산학협력단 | Amd3100을 포함하는 골질환 예방 또는 치료용 조성물 |
| US20180112180A1 (en) | 2015-01-26 | 2018-04-26 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
| CN104774806B (zh) * | 2015-04-09 | 2019-02-15 | 广州赛莱拉干细胞科技股份有限公司 | 一种胎盘造血干细胞的制备方法 |
| US20180214487A1 (en) | 2015-07-21 | 2018-08-02 | The Children's Medical Center Corporation | Pd-l1 expressing hematopoietic stem cells and uses |
| IL261002B2 (en) | 2016-02-12 | 2024-07-01 | Bluebird Bio Inc | Vcn enhancer compositions and methods of using the same |
| WO2017139561A1 (en) | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| EP3419617A4 (en) * | 2016-02-26 | 2019-10-23 | President and Fellows of Harvard College | HIGH GRADE TRANSPLANTABLE HEMATOPOETIC STEM CELLS |
| WO2018017341A1 (en) * | 2016-07-22 | 2018-01-25 | Senlin Li | Methods and compositions for rejuvenation |
| EP3548425B1 (en) | 2016-12-02 | 2023-03-29 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| EP3574088A4 (en) * | 2017-01-27 | 2020-09-23 | Children's Hospital Medical Center | PROCESSES FOR IMPROVING HEMATOPOIETIC STEM CELL TRANSPLANT ACTIVITY |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| US11213546B2 (en) | 2017-09-07 | 2022-01-04 | Emory University | Methods to mobilize tissue resident cells for adoptive t cell therapy |
| US11879137B2 (en) | 2017-09-22 | 2024-01-23 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
| FR3074189A1 (fr) * | 2017-11-30 | 2019-05-31 | Assistance Publique - Hopitaux De Paris | Methode de generation de greffons de cellules souches hematopoietiques |
| CN108404112B (zh) * | 2018-04-01 | 2020-05-12 | 北京诺赛启研再生医学研究院有限公司 | 提高造血干细胞归巢及植入率的方法及其试剂 |
| EP3647413A1 (en) * | 2018-10-31 | 2020-05-06 | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas O.A., M.P. (CIEMAT) | Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation |
| CN113874033A (zh) | 2019-04-08 | 2021-12-31 | 泰加生物工艺学公司 | 用于冷冻保存免疫细胞的组合物和方法 |
| EP3969041A4 (en) | 2019-05-14 | 2023-05-10 | Taiga Biotechnologies, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION |
| KR20220160018A (ko) | 2020-03-31 | 2022-12-05 | 덴카 주식회사 | 알루미나 분말, 수지 조성물, 및 방열 부품 |
| CN116509834B (zh) * | 2023-01-20 | 2025-05-13 | 东北师范大学 | 化合物在制备造血干/祖细胞增殖和损伤修复药物中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399493A (en) * | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| JPH08205860A (ja) * | 1994-01-21 | 1996-08-13 | Usa Government | 造血細胞の膨大化および移植方法 |
| US5928638A (en) * | 1996-06-17 | 1999-07-27 | Systemix, Inc. | Methods for gene transfer |
| RU2305708C2 (ru) * | 2001-10-02 | 2007-09-10 | Энститю Клейтон Де Ля Решерш | Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение |
| EP1461087A1 (en) * | 2001-12-06 | 2004-09-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders |
| WO2003065871A2 (en) * | 2002-02-04 | 2003-08-14 | Millennium Pharmaceuticals Inc. | Methods and compositions for treating hematological disorders |
| EP1613742A2 (en) | 2003-04-08 | 2006-01-11 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same |
| IL158868A0 (en) | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
| JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| US20080021078A1 (en) | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| US20070087988A1 (en) | 2005-09-30 | 2007-04-19 | New York University | Hematopoietic progenitor kinase 1 for modulation of an immune response |
| JP2007099724A (ja) | 2005-10-06 | 2007-04-19 | Shizuoka Prefecture | スルファチドを標的とした抗ウイルス剤 |
| WO2007047372A2 (en) * | 2005-10-14 | 2007-04-26 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists |
| RU2425876C2 (ru) | 2006-03-24 | 2011-08-10 | Чилдрен'З Медикал Сентер Корпорейшн | Способ модулирования роста гематопоэтических стволовых клеток |
| WO2007148332A1 (en) | 2006-06-22 | 2007-12-27 | Yeda Resaerch And Development Co. Ltd | Catecholamine receptor modulation |
| EP3824885A1 (en) | 2006-10-20 | 2021-05-26 | Children's Medical Center Corporation | Method to enhance tissue regeneration |
| EP2094839B1 (en) * | 2006-12-08 | 2020-02-05 | University of Rochester | Expansion of hematopoietic stem cells |
| US8598328B2 (en) | 2006-12-13 | 2013-12-03 | National University Corporation Nagoya University | Tol1 factor transposase and DNA introduction system using the same |
| CN108379292A (zh) | 2008-11-06 | 2018-08-10 | 印第安纳大学研究与技术公司 | 增强造血干细胞植入过程的材料和方法 |
| WO2010108028A2 (en) | 2009-03-19 | 2010-09-23 | Fate Therapeutics, Inc. | Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
| ES2769270T3 (es) | 2011-09-30 | 2020-06-25 | Bluebird Bio Inc | Compuestos para transducción viral mejorada |
-
2009
- 2009-11-06 CN CN201810232658.3A patent/CN108379292A/zh active Pending
- 2009-11-06 EP EP09825528.4A patent/EP2362733B1/en not_active Not-in-force
- 2009-11-06 EP EP20195600.0A patent/EP3824884A1/en not_active Withdrawn
- 2009-11-06 CN CN201710777353.6A patent/CN107523587A/zh active Pending
- 2009-11-06 CN CN201710777354.0A patent/CN107630001A/zh active Pending
- 2009-11-06 US US13/128,074 patent/US9107909B2/en active Active
- 2009-11-06 ES ES16153526T patent/ES2845641T3/es active Active
- 2009-11-06 CN CN2009801495225A patent/CN102245758A/zh active Pending
- 2009-11-06 WO PCT/US2009/063654 patent/WO2010054271A1/en not_active Ceased
- 2009-11-06 CA CA3203374A patent/CA3203374A1/en active Pending
- 2009-11-06 CA CA3012803A patent/CA3012803C/en active Active
- 2009-11-06 PT PT161535265T patent/PT3031907T/pt unknown
- 2009-11-06 AU AU2009313290A patent/AU2009313290B2/en not_active Ceased
- 2009-11-06 JP JP2011534934A patent/JP5846915B2/ja not_active Expired - Fee Related
- 2009-11-06 EP EP16153526.5A patent/EP3031907B1/en not_active Revoked
- 2009-11-06 CA CA2742876A patent/CA2742876C/en active Active
-
2014
- 2014-06-27 US US14/318,167 patent/US10213460B2/en active Active
-
2015
- 2015-03-04 US US14/638,676 patent/US9675641B2/en not_active Expired - Fee Related
- 2015-07-03 JP JP2015134076A patent/JP6632822B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-21 AU AU2016206316A patent/AU2016206316C1/en not_active Ceased
-
2017
- 2017-05-11 US US15/592,375 patent/US11241454B2/en not_active Expired - Fee Related
- 2017-10-05 JP JP2017195168A patent/JP2018048156A/ja not_active Withdrawn
-
2018
- 2018-07-23 ZA ZA2018/04932A patent/ZA201804932B/en unknown
- 2018-10-08 AU AU2018241208A patent/AU2018241208B2/en not_active Ceased
-
2019
- 2019-11-29 JP JP2019217044A patent/JP2020063263A/ja not_active Withdrawn
-
2020
- 2020-08-21 AU AU2020220191A patent/AU2020220191B2/en not_active Ceased
-
2021
- 2021-12-14 US US17/550,737 patent/US20220313735A1/en not_active Abandoned
-
2023
- 2023-01-06 JP JP2023001015A patent/JP2023052244A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020063263A5 (https=) | ||
| Benjamin et al. | TALEN gene editing takes aim on HIV | |
| SA517390590B1 (ar) | Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة | |
| MY197586A (en) | Adenovirus armed with bispecific t cell engager (bite) | |
| JP2018184448A5 (https=) | ||
| CO2021006362A2 (es) | Construcciones de ácido nucleico y métodos de uso | |
| US12485187B2 (en) | Method for improving retroviral transduction and gene editing in hematopoietic stem cells using clyclosporin H and UM171 | |
| CO2020010376A2 (es) | Uso de vectores lentivirales que expresan el factor viii | |
| MX2025013445A (es) | Generacion de pah humana mejorada para el tratamiento de pku grave mediante terapia de sustitucion de genes dirigida al higado | |
| MY209906A (en) | Lipid nanoparticle formulations of non-viral, capsid-free dna vectors | |
| Kawashima et al. | Properties of dental pulp–derived mesenchymal stem cells and the effects of culture conditions | |
| MX2021001292A (es) | Metodos para la modificacion genica de celulas hematopoyeticas. | |
| MX2022010363A (es) | Formulaciones clinicas. | |
| MX2020005663A (es) | Terapia genica para mucopolisacaridosis iii a. | |
| MX2024012761A (es) | Terapia genica con el atanogeno 3 asociado a linfoma de celulas b 2 (bag3) utilizando el vector aav | |
| MX2024005314A (es) | Particulas virales redirigidas a musculo esqueletico. | |
| CO2023015911A2 (es) | Vectores aavrh74 para la terapia génica de distrofias musculares. | |
| WO2021081457A3 (en) | Methods and agents for enhancing t cell therapies | |
| Zhou et al. | IFNα‐expressing amniotic fluid‐derived mesenchymal stem cells migrate to and suppress HeLa cell‐derived tumors in a mouse model | |
| Díaz et al. | GFP labelling and epigenetic enzyme expression of bone marrow-derived mesenchymal stem cells from bovine foetuses | |
| MX2021013597A (es) | El polipeptido ix adenoviral aumenta la productividad y la infectividad del vector adenoviral de terapia genica. | |
| CA3217059A1 (en) | Compositions for improving the transduction of cells by viral vectors | |
| Sorg et al. | O6-methylguanine-DNA-methyltransferase (MGMT) gene therapy targeting haematopoietic stem cells: studies addressing safety issues | |
| Aizenshtadt et al. | Charachterization of umbilical cord mesenchymal stromal cells during long-term expansion in vitro | |
| EP1533381A4 (en) | VECTOR OF ADENOVIRUS |